Join Dr Ashish Sharma, an ophthalmologist at Lotus Eye Hospital and Institute in India, to learn some fast facts about biosimilars in retinal disease.
- Expand your knowledge on the biosimilar development and approval process, and learn why biosimilars have only recently arrived on the market for retinal disease
- Since the first ophthalmology biosimilar was approved in Europe and the US, learn about its clinical effectiveness and safety profile, and other biosimilars in the pipeline
- Explore how early and sustained treatment can achieve better outcomes for patients with retinal disease, and how biosimilars can improve access to care
Meet the expert
Dr Sharma is an ophthalmologist at Lotus Eye Hospital in Coimbatore, India. He has published over 90 peer-reviewed articles and book chapters, and is principal investigator on an EMA and FDA phase 3 clinical trial of newer anti-VEGFs. He is also on the reviewing and editorial board of high impact ophthalmology journals. He has been awarded an International Ophthalmologist Education Award by American Academy of Ophthalmology Board of trustees and Ophthalmic Hero of India by All India Ophthalmic Society.
Disclosures: Dr Sharma has been a consultant and speaker for Intas, Lupin, Novartis and Bayer
This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.